RedHill Biopharma (RDHL) Asset Writedowns and Impairment (2017 - 2022)

RedHill Biopharma (RDHL) has 4 years of Asset Writedowns and Impairment data on file, last reported at $1.5 million in Q4 2022.

• On a quarterly basis, Asset Writedowns and Impairment fell 85.88% year-over-year to $1.5 million in Q4 2022; TTM through Dec 2022 was $6.0 million, a 62.93% decrease from a year earlier, with the FY2022 full-year figure at $6.0 million, down 62.93% from the prior year.
• Asset Writedowns and Impairment for Q4 2022 stood at $1.5 million, down from $1.6 million in the prior quarter.
• Over the last five years, Asset Writedowns and Impairment for RDHL reached as high as $10.7 million in Q4 2021 and fell as low as $1.1 million in Q1 2020.
• Historically, Asset Writedowns and Impairment has averaged $2.4 million across 3 years, with a median of $1.8 million in 2020.
• Across the five-year window, Asset Writedowns and Impairment soared 417.28% in 2021 and tumbled 85.88% in 2022, its largest moves.
• Year by year, Asset Writedowns and Impairment stood at $2.1 million in 2020, then surged by 417.28% to $10.7 million in 2021, then tumbled by 85.88% to $1.5 million in 2022.
• Per Business Quant data, the three most recent Asset Writedowns and Impairment figures were $1.5 million in Q4 2022, $1.6 million in Q3 2022, and $1.3 million in Q2 2022.